Isolated
inflammatory demyelinating disorders
Experimental
allergic encephalomyelitis
Acute
disseminated encephalomyelitis
Multiple sclerosis (MS) is now known
to be a common malady even though it was first recognized as a distinct
clinicopathological entity less than 150 years ago. The lack of reports before
the early 1800s is sometimes interpreted as evidence that MS is a relatively
new disease. However, it is more likely that the evolution of medicine as a
science, which began at approximately the same time, led to more precise observation
and description of human diseases. This view is strengthened by the observation
of what may be the earliest clinical description of MS: the case of St. Lidwina
of Schiedam (1380-1433), who developed a relapsing neurological disorder at the
age of 18. аOllivier was the first to report a clinical case in the medical
literature in 1824. Shortly thereafter, Carswell illustrated a case of what is
now clearly recognizable as MS in his atlas of anatomical pathology. Cruveilhier
published gross pathological descriptions of MS together with clinical case
descriptions. Although others certainly contributed (including Frerichs,
Valentiner, Turck, Rokitansky, and Rindfleisch), Vulpian first suggested the
rubric of "sclerose en plaque" in 1866. Charcot was primarily
responsible for establishing MS as a unique and recognizable syndrome. He also
described the clinical spectrum and the histological appearance. Pierre Marie
was the first to suggest an infectious cause of MS in 1884, a hypothesis that
is still debated. Toxins were also considered to be responsible in the early
1900s. A major advance toward the understanding of demyelinating diseases was
the discovery of experimental allergic encephalomyelitis (EAE) by Rivers in
1935. A variety of different demyelinating diseases have subsequently been
described ( Table 48-1 ).
Myelin provides insulation for axons
and is necessary for saltatory conduction. It is composed of tightly wrapped
lipid bilayers with specialized protein constituents. Peripheral nervous system
(PNS) myelin is formed by the extension of Schwann cells, and central nervous
system (CNS) myelin is produced by oligodendrocytes. As the cell processes wrap
around the axon, cytoplasm is extruded, leaving the inner (cytoplasmic) and
outer (extracellular) plasma membrane leaflets in close apposition. Electron
microscopy reveals several dozen spirals containing dense lines. The darker,
major dense line is formed by the apposition of the inner leaflets, and the
lighter, intraperiod line is formed by the close approximation of outer
leaflets (Fig. 48-1 (Figure Not Available) ). The myelin coating is interrupted
at regular intervals (nodes of Ranvier) where the axon membrane with its
concentration of voltage-gated sodium channels is exposed to the extracellular
environment.
CNS and PNS myelin differ in a
number of important ways. Schwann cells myelinate only one internodal segment
from a single PNS axon, whereas oligodendrocytes myelinate multiple CNS axons.
The proteins also differ. Proteolipid protein (PLP) accounts for approximately
50 percent of the CNS myelin proteins. PLP is an integral membrane protein
responsible for holding the outer
TABLE 48-1 -- PRIMARY (IDIOPATHIC)
INFLAMMATORY DEMYELINATING DISORDERS OF THE CENTRAL NERVOUS SYSTEM |
Acute
disseminated encephalomyelitis |
Monophasic |
Multiphasic |
Relapsing
(controversial) |
Monosymptomatic
syndromes |
Optic
neuritis |
Acute
transverse myelitis (partial and complete) |
Brain
stem demyelination |
Multiple
sclerosis |
Neuromyelitis
optica |
Marburg's
disease |
Schilder's
myeloclastic diffuse sclerosis (controversial) |
Balo's
concentric sclerosis |
leaflets
together at the intraperiod line. Mutations in this highly conserved protein
cause Pelizaeus-Merzbacher disease. Protein zero (P0) is the major PNS myelin
protein and performs a function similar to PLP in compacting the intraperiod
line. Myelin basic protein (MBP) makes up 30 percent of CNS and 10 percent of
PNS myelin proteins. MBP is not an integral protein but binds to the cytoplasmic
surface and is responsible for compaction at the major dense line. Myelin
associate glycoprotein (MAG) accounts for about 1 percent of both peripheral
and central myelin. Myelin oligodendrocyte glycoprotein (MOG) and cyclic
nucleotide phosphodiesterase (CNP) are minor constituents of CNS myelin and are
not found in the PNS. Peripheral myelin protein 22 (PMP22) is a minor component
of PNS myelin.
Multiple sclerosis is an
inflammatory relapsing or progressive disorder of CNS white matter and a major
cause of disability in young adults. Pathologically, it is characterized by
multifocal areas of demyelination with relative preservation of axons, loss of
oligodendrocytes, and astrogliosis. Although certain clinical features are
characteristic of MS, investigative studies are often needed to confirm the
clinical suspicion and exclude other possibilities. These tests may be useful
in monitoring disease activity in patients with MS. Recently, there have been advances
in our understanding of the etiology, mechanisms of myelin injury, and
potential for repair. Although ideal treatment does not exist, several new
therapies are being investigated and others are or soon will be available for
use.
Pathogenesis and
Pathophysiology. The pathogenesis and pathophysiology of MS is at
best incompletely understood. There are several proposed mechanisms that may be
important in the production of MS plaques: autoimmunity, infection, bystander
demyelination, and heredity. Although convincing proof is lacking, dietary
factors and toxin exposure have been hypothesized to contribute as well. These
mechanisms are not mutually exclusive, and the true pathophysiology is likely
to depend on more than one of them.
Autoimmunity.
During ontogenesis, autoreactive lymphocytes normally undergo clonal depletion,
but some escape and are merely suppressed, becoming tolerant of their antigens.
Low levels of autoreactive T and B cells persist even in normal individuals.
Autoimmune disorders occur when the tolerance of these cells toward their
antigen is broken. The decreased suppressor activity of circulating lymphocytes
from patients with MS and other presumed autoimmune diseases may reflect loss
of tolerance. One potential mechanism that may break tolerance is molecular
mimicry between self and foreign antigens. Autoreactive T4 lymphocytes may
become activated on exposure to structurally similar foreign antigens. Some
evidence suggests that molecular mimicry is relevant in MS. Not only do several
viral and bacterial peptides share structural similarities with MBP, but it has
also been demonstrated that a few of them are able to activate MBP-specific
T-cell clones derived from MS patients. Blood-brain barrier leakage alone may
break tolerance because it gives CNS-reactive lymphocytes easy access to
otherwise inaccessible antigens. Alternatively, a primary event such as an
infection or injury may release CNS antigens into the periphery, where they may
activate corresponding autoreactive cells. The major support for autoimmunity
in the pathogenesis and pathophysiology of MS is by analogy to EAE, the major
animal model for MS (see later). EAE is, however, an artificial situation and
there is no spontaneous autoimmune animal model of MS.
MBP has been the leading candidate
for the autoimmune target in MS because of its ability to induce EAE. Humoral
and T-cell immune responses to MBP are found in the blood of both MS patients
and healthy controls, although the level may be higher in actively relapsing MS
patients. MBP-reactive T-cells activated in vivo have also been identified in
peripheral blood of MS patients. In the cerebrospinal fluid (CSF), MBP-reactive
B and T lymphocytes and anti-MBP IgG are often present in patients with MS and
other neurological diseases. The level of these findings seems to correlate
with the extent of tissue injury but not necessarily with the etiology. Immune
responses toward other CNS antigens have not been investigated as thoroughly
but could be important. The findings of MBP-specific T and B cells in CSF and
MBP-specific B cells and possibly T cells within CNS lesions leave little doubt
as to the existence of an autoimmune response in MS. Because this response may
be secondary to the release of sequestered CNS antigens by a primary event, it
is uncertain if and to what extent autoimmunity is responsible for the
pathology.
Infection. The
role of viral infections in the initiation and maintenance of MS has been
debated for some time. Several viral infections are known to cause demyelination
in animals, including visna virus of goats and sheep, canine distemper virus,
and Theiler's murine encephalomyelitis virus (TMEV). Viral infections in humans
can also cause demyelination (progressive multifocal leukoencephalopathyа JC papilloma virus , subacute sclerosing
panencephalitisа measles virus , and
human T-cell lymphotropic or leukemia virus type Iа HTLV-I -associated myelopathy). The epidemiology of MS suggests
that environmental factors may promote the disease state, possibly due to one
or more viruses. There are many ways in which a virus may be involved in the
pathogenesis of MS:
Beyond speculation and epidemiology,
there is slim evidence for a viral infection in MS. Early serological studies
are difficult to interpret because of the nonspecific immune activation and
resulting elevation of titers to many different viruses. Many MS patients have
elevated CSF titers to such viruses as measles and herpes simplex (HSV), but
this also appears nonspecific. Virus has rarely been cultured from CSF of MS
patients, but a new strain of HSV (the MS strain) and a new virus
(Inoue-Melnick virus) were first isolated from the CSF of MS patients Newer molecular techniques to search for a viral
genome in CSF and brain have rejected the claim that HTLV-I is associated with
MS. In addition, reverse transcriptase activity has not been detected in CSF
using a very sensitive assay, thus disputing the involvement of any retrovirus.
The finding that human herpesvirus 6, although present in 70 percent of brains
from both controls and MS patients, is localized to the oligodendrocyte nuclei
near plaques of MS patients and to oligodendrocyte cytoplasm in controls
indicates that persistent CNS viral infection is common. This raises the
possibility that MS may depend on an aberrant host response to this normal
condition or that a defective virus that lacks the ability to evade immune
detection may be to blame.
"Bystander"
Demyelination. Immune actions may mediate myelin injury in a
nonspecific manner. Many soluble products of the immune response other than
immunoglobulins are known or suspected to be toxic to myelin and
oligodendrocytes. Activated complement is capable of lysing oligodendrocytes in
an antibody-independent fashion.а аThe proinflammatory cytokine tumor necrosis
factor-alpha causes myelin disruption and oligodendrocyte apoptosis in vitro.а аArachidonic acid metabolites may also
participate in myelinolysis, and reactive oxygen species released by
macrophages cause lipid peroxidation that can damage myelin. Other soluble
substances that are potentially toxic to myelin include nitrous oxide and
vasoactive amines.
Heredity.
Epidemiological findings support a polygenic hereditary predisposition to MS. A
number of candidate genes have been investigated, often with contrary results.
The only definitively proven genetic association in MS is with serologically
defined human leukocyte antigen (HLA) DR15, DQ6 (one of the DR2 haplotypes and
also known as Dw2 in cellular terminology and DRB1*1501, DQA1*0102, DQB1*0602
in molecular nomenclature). However, the risk conferred by this haplotype is
small (relative risk of 3 to 4), and it is neither necessary nor sufficient for
the development of MS. Linkage to this locus has not been proven, indicating
that it plays only a minor role in familial susceptibility. Other
susceptibility genes undoubtedly contribute and may include the T-cell receptor
(TCR) variable beta region and the IgG heavy-chain variable region, but these
have not been confirmed. Twenty percent of MS patients have at least one
affected relative. Only about 4 percent of first-degree relatives of patients
develop MS, but this represents a 20- to 40-fold increase in risk compared with
the general population. Unaffected family members sometimes have abnormal
results of head magnetic resonance imaging (MRI), implying that this risk is
even higher. One study of MS rates in adopted relatives of MS patients verified
that the familial distribution is due to genetic factors rather than shared
environment.а
аTwin studies
lend support to both genetic and environmental influences on MS development.
Genetically identical monozygotic twins are more often concordant for MS than
dizygotic twins (26 percent and 2.4 percent, respectively), indicating a
genetic componentа а; however, even after following monozygotic
twins past age 50 or using MRI data, less than 50 percent are concordant,
suggesting a role for environmental factors.
Epidemiology and
Risk Factors. MS is not a rare disease. It affects millions
worldwide and approximately 400,000 in the United States alone. Symptoms
usually begin during young adulthood, with the peak onset at age 24. Generally
it occurs in persons between the ages of 15 and 50, although the first
manifestations occasionally start during childhood or after age 50. Women are
affected nearly twice as often as men. MS has a predilection for whites,
especially those of northern European heritage. Other races and ethnic
populations are resistant to a variable extent. It is virtually unknown among
black Africans but occurs in African-Americans at half the rate of whites,
possibly due to racial admixture or environmental factors. MS is rare in
tropical areas, and the prevalence increases proportional to the distance from
the equator, excluding polar regions. Although usually interpreted as the
effect of environmental factors, the prevalence gradient is at least partially
due to racial susceptibility.а а
Perhaps the most incriminating
evidence for the role of environmental factors in the development of MS are the
changing risk with migration and the occurrence of MS clusters and epidemics.
Immigrant populations tend to acquire the MS risk inherent to their new place
of residence. Furthermore, the age at immigration is important in the
subsequent risk of MS. Migration from high to low prevalence before the age of
15 lowers the MS risk, whereas migration after this age does not affect risk.а аMigration from low to high prevalence areas
increases the risk of MS, but the effect of age is less clear. Many clusters of
MS have been reported. One of the more notable ones occurred in Key West in the
mid 1980s.а аSeveral others have been disputed; and
despite wide speculation, no environmental cause for clustering has been
identified. In fact, the majority of community-identified clusters are likely
due to statistical chance aloneThe occurrences of MS epidemics in Iceland and
the Faroe Islands have been proposed to be the result of exposure to a pathogen
brought by British troops during their occupation in World War II.
Epidemiological data support the
view that MS is caused or triggered by an environmental factor in persons who
are genetically susceptible. The familial frequency and distribution implies
that several genes contribute to susceptibility, and this is consistent with
the low relative risk conferred by the genetic loci studied so far. Data from
clusters, migration studies, and family studies reveal that there is a latent
period of some 20 years between exposure to the environmental factor and the
development of clinical symptoms and that the age at exposure is around 15, the
putative age at acquisition.
The precise environmental events
that lead to CNS demyelination are uncertain. Viral infection is the most
plausible, but because of the nonspecific elevation of viral titers and long
latent period there is little direct evidence. Minor respiratory infections
precede 27 percent of relapses in patients with established MS. Measles
infection was found to have occurred at a later age in MS patients than
controls, although the incidence of MS has not been reduced by immunization
against measles. Head injury and trauma have received attention as putative
triggering events, but cohort studies have not verified any link. Pregnancy
does not alter the risk of developing MS, but it does seem to influence disease
activity. The relapse rate drops by about one third during the last two
trimesters, but this is offset by an increase in relapse rate in the postpartum
period. Most studies have found no long-term effects of pregnancy on the
prognosis for progression or disability, although one did report a favorable
effect.а аA multitude of other environmental factors
have been suspected to alter the risk for MS (cold climate, precipitation,
amount of peat in the soil, exposure to dogs, and consumption of meat,
processed meat, and dairy products), but none has been verified to be an
independent risk factor.
Clinical Features
and Associated Findings. MS can cause a wide variety of clinical features.
Many signs and symptoms are characteristic, and a few are virtually
pathognomonic for the disorder. Conversely, some symptoms are atypical and some
are so rare as to suggest a different diagnosis ( Table 48-2 ). The course of
the illness is also variable, but it remains a critical consideration in the
diagnosis of MS.
Sensory symptoms are the most common
presenting manifestation in MS and ultimately develop in nearly all patients.
Loss of sensation (numbness), paresthesias (tingling), dysesthesias (burning),
and hyperesthesias are common. These may occur in practically any distribution:
one or more limbs, part of a limb, trunk, face, or combinations.
The more distinctive sensory
relapses of MS consist of the sensory cord syndrome and the useless hand
syndrome.
TABLE 48-2 -- DIAGNOSIS OF MULTIPLE
SCLEROSIS |
|
|
Clinical
Features Suggestive of MS |
Clinical
Features Not Suggestive of MS |
|
Onset
between the ages of 15 and 50 |
Onset
before the age of 10 or after 55 |
|
Relapsing/remitting
course |
Continued
progression from onset without relapses |
|
Optic
neuritis |
|
|
Lhermitte's
sign |
Early
dementia |
|
Partial
transverse myelits |
Seizures |
|
Internuclear
ophthalmoplegia |
Aphasia |
|
Sensory
useless hand |
Agnosia |
|
Acute
urinary retention (especially in young men) |
Apraxia |
|
Homonymous
or bitemporal hemianopia |
||
Paroxysmal
symptoms |
|
|
Diurnal
fatigue pattern |
Encephalopathy |
|
Worsening
symptoms with heat or exercise |
Extrapyramidal
symptoms |
|
Uveitis |
|
|
Peripheral
neuropathy |
|
|
Whereas
features listed in the right column may be seen in MS, they are atypical and
should prompt consideration of alternate explanations. |
|
A common scenario is that of numbness or tingling beginning in one foot,
ascending first ipsilaterally and then contralaterally. The sensory symptoms
may ascend to the trunk, producing a sensory level, or may involve the upper
extremities. Associated symptoms commonly include poor balance, weakness,
urinary urgency, constipation, and Lhermitte's sign (see later). Brown-Sequard
syndrome may occur with sensory disassociation and hemiparesis. The sensory
cord syndrome reflects an evolving demyelinating lesion that begins in the
medial posterior column ipsilateral to the first symptoms. A suspended sensory
loss on one side of the trunk may also occur, possibly involving the upper
extremity. Sensory cord syndromes are common in MS and suggest the diagnosis
when they occur in young persons and remit spontaneously or in response to
corticosteroids. Patients with the sensory useless hand may note subjective
numbness and lose discriminatory and proprioceptive function, resulting in difficulty
writing, typing, buttoning clothes, and holding on to objects especially when
not looking at their hand. This can occur bilaterally even without lower
extremity symptoms. The responsible lesion is in the lemniscal pathways either
in the cervical spinal cord or in the brain stem. This syndrome usually remits
over several months. The useless hand syndrome is a very specific symptom and
is only rarely caused by other disorders.
A large portion of MS patients have
persistent sensory loss usually consisting of diminished vibratory and position
sensation in distal extremities. Itching may occur in a dermatomal distribution
with relapse or in paroxysms. Pain is not a major manifestation of MS, but when
it does occur it can be distressing to the patient. The most common complaints
of pain are lower extremity dysesthetic pain associated with spinal cord
involvement, radicular pain from lesions at the root entry zone, paroxysms (see
later), and an uncomfortable sensation of pressure or tightness surrounding a leg
or the trunk.
Pyramidal tract dysfunction is
common in MS and causes weakness, spasticity, loss of dexterity, and
hyperreflexia. Motor deficits can occur acutely or in a chronic progressive
fashion and are usually accompanied by other symptoms. Paraparesis,
quadriparesis, hemiparesis, weakness of one limb, and facial weakness are
common manifestations. Subtle deficits are frequently worsened by exercise or
heat. Weakness of trunk muscles resulting from spinal cord lesions may cause
abnormal posture and occasionally respiratory muscle weakness occurs from cord
or brain stem lesions. Symptoms of spasticity such as leg stiffness that
impairs gait and balance or extensor and flexor spasms are other major causes
of disability. Muscle atrophy is usually due to disuse, but lesions of the
exiting lower motor neuron fibers or of the anterior horn itself can cause a
pseudora-diculopathy with segmental weakness, atrophy, and diminished reflexes.
The initial symptom of MS is optic
neuritis in 17 percent of patients, and more than 50 percent experience a
clinical episode of optic neuritis during their lifetime. The most common
manifestation is visual loss in one eye that evolves over a few days.
Periocular pain, especially with eye movement, usually accompanies and may precede
the visual symptoms. Bilateral simultaneous optic neuritis is uncommon in
adults, but formal visual field testing reveals unexpected defects in the
clinically normal eye in a substantial number of patients. Children and Asian
patients are more likely to have bilateral simultaneous optic neuritis.
Examination shows an afferent pupillary defect, diminished visual acuity,
subdued color perception, and often a central scotoma. Funduscopic examination
is usually normal but occasionally will reveal papillitis (more common in
children) or venous sheathing. Most patients begin to recover within 2 weeks,
and significant visual recovery is common. There may be persistent visual
blurring, altered color perception, or Uhtoff's sign (see later). Progressive
worsening of visual acuity sometimes occurs, and MS patients without a clinical
history of optic neuritis often have evidence of optic nerve involvement on
funduscopic examination or visual evoked potentials.
Cerebellar pathways are frequently
involved during the course of MS, but a predominately cerebellar syndrome is
uncommon at onset. The manifestations include dysmetria, dysdiadochokinesia,
action tremor with terminal accentuation, dysrhythmia, breakdown of complex
motor movements, and loss of balance. Symptoms range from mild dyscoordination
or gait unsteadiness to violent movement-induced tremor and complete loss of
balance. Patients with long-standing MS may develop a "jiggling" gait
and an ataxic dysarthria with imprecise articulation, scanning speech, or
varying inflection, giving it an explosive character.
Urinary urgency, frequency, and urge
incontinence (due to detrusor hyperreflexia or detrusor-sphincter dyssynergia)
result from spinal cord lesions and are frequently encountered in MS patients.
Symptoms of bladder dysfunction may be transient and occur with an exacerbation
but are commonly persistent. Impaired vesicular sensation causes a high
capacity bladder and may lead to bladder atonia with thinning and disruption of
the detrusor muscle. This is an irreversible condition in which overflow
incontinence results in constant dribbling of urine. Interruption of brain stem
micturition center input sometimes leads to co-contracture of the urinary
sphincter and detrusor muscles or detrusor-sphincter dyssynergia. The resulting
high pressure may lead to hydronephrosis and chronic renal failure if
untreated. Constipation is a common problem, especially in patients with
limited activity and spinal cord involvement. Fecal incontinence is a socially
devastating symptom that is often associated with perineal sensory loss in MS
patients.
Sexual dysfunction is a common
problem of MS that is seldom mentioned. Nearly two thirds of patients report
diminished libido. One third of men have some degree of erectile dysfunction,
and a similar percentage of women have deficient vaginal lubrication. Besides
direct neurological impairment, sensory loss, physical limitations, depression,
and fatigue additionally contribute to sexual difficulties in MS patients. In
addition, the partner's attitude and psychological factors dealing with
self-image, self-esteem, and fear of rejection may also lead to impotence or
loss of libido.
Intense vertigo associated with
nausea and emesis is an occasional manifestation of MS relapse. In the absence
of a clear diagnosis of MS, these symptoms are often attributed to vestibular
neuronitis. Patients may also develop more persistent mild vertigo that is
precipitated by movement, or this may be the residua after an acute relapse.
Internuclear ophthalmoplegia, caused by a lesion in the medial longitudinal
fasciculus, is the most common cause of diplopia in MS patients. When
symptomatic, it produces horizontal diplopia on lateral gaze that usually
remits. Examination discloses incomplete or slow adduction of the eye
ipsilateral to the lesion and nystagmus of the contralateral eye during
abduction. Dissociated nystagmus may be the only finding of an old or subtle
internuclear ophthalmoplegia. Bilateral internuclear ophthalmoplegias are
strongly suggestive of MS, although they rarely occur with tumor, infarct,
mitochondrial cytopathy, Wernicke's encephalitis, and Chiari malformation.
Vertical and diagonal diplopia usually result from skew deviation. Nystagmus,
slow saccadic movements, broken ocular pursuits, and ocular dysmetria are other
eye findings produced by lesions of cerebellar and vestibular pathways. Cranial
nerve impairment is an unusual cause of diplopia in MS patients. Abducens
paresis occurs on occasion, but oculomotor and trochlear nerve impairment are
rare.
Brain stem plaques are seen on MRI
more often than the occurrence of acute brain stem relapses. Corticospinal,
spinothalamic, lemniscal, vestibular, and cerebellar pathways can all be
affected. In addition, cranial nerve impairment may be seen with lesions that
affect brain stem nuclei or exiting and entering fibers. Usually this occurs in
association with other symptoms. Because of the long spinal tract and nucleus,
the trigeminal nerve is frequently involved. Facial nerve paresis does occasionally
occur, but MS is an extremely rare cause of Bell's palsy in patients without
previous symptoms. Acute unilateral hearing loss is a fairly uncommon
manifestation. Dysphagia is often due to impairment of cranial nerves IX, X,
and XII and generally appears late in the course of some patients.
Once thought uncommon, cognitive
disorders are now known to be present in 40 to 70 percent of MS patients.а аAge, duration of MS, and physical disability
do not predict the presence of cognitive dysfunction, but the total lesion load
seen on MRI does seem to correlate with the degree of cognitive decline. Brain
atrophy, enlarged ventricles, and thinning of the corpus callosum also portend
symptoms of cognitive dysfunction. Often the problems are subtle and may not be
detected on standard mental status evaluation. The pattern of cognitive decline
in MS is typified by memory loss, inattention, slow information processing, and
difficulty with abstract concepts and complex reasoning. General intelligence
is not typically affected. As expected, cortical symptoms such as aphasia,
apraxia, and agnosia are distinctly unusual. Homonymous hemianopia, which can
be caused by cortical or subcortical lesions, is also uncommon. Despite
prominent cerebral white matter involvement, many of the disconnection
syndromes such as alexia without agraphia, conduction aphasia, and pure word
deafness have not been reported in MS patients.
Affective disorders are more
frequent in MS patients than in the general population. These include both anxiety
and depression. Neither of these symptoms is related to physical or cognitive
disability or the lesion load visualized by MRI. Patients sometimes experience
uncontrollable weeping or less commonly laughter noncongruent with their mood.
Interruption of inhibitory corticobulbar fibers is responsible for these
symptoms (pseudobulbar affect).
Fatigue is a pervasive symptom among
MS patients that is not related to disability or depression. Severely affected
patients often have a lack of initiative for both physical and mental activity
and become easily tired. A diurnal pattern is characteristic and follows the
normal circadian pattern of body temperature fluctuations, with the worse
symptoms occurring in afternoon hours (peak core body temperature) giving way
to improvement in the late evening.
MS symptoms may fluctuate in a
predictable fashion. Transient worsening of symptoms frequently follows
exercise or elevation of body temperature. One example is Uhtoff's phenomenon,
in which visual blurring occurs during strenuous activity or with passive
exposure to heat. These episodes resolve when the body temperature cools to
normal or after a period of rest. An intercurrent infection with fever can
induce worsening of symptoms and may be confused with a relapse. Heat
sensitivity is presumably related to conduction block because demyelinated
axons are more prone to failed conduction than normal, myelinated fibers.
Paroxysmal symptoms are
characteristic of MS. They are believed due to the lateral spread of excitation,
or ephaptic transmission, between denuded axons in areas of demyelination.
Symptoms are typically brief in duration (seconds to 2 minutes) and occur
frequently, occasionally dozens of times per day. They may be precipitated by
hyperventilation, certain sensory input, or particular postures. Tonic spasms
(paroxysmal dystonia) most often affect the arm and leg on one side, but the
face, one limb, or bilateral limbs are sometimes involved. These spasms can
result from lesions anywhere along the corticospinal tract. They often begin
during the recovery phase after an acute relapse and remit after a few months.
Intense pain and ipsilateral or crossed sensory symptoms may accompany them.
Paroxysmal weakness occurs, but it is uncommon.
A wide variety of paroxysmal sensory
symptoms may occur with MS, including tingling, prickling, burning, or itching;
and sharp neuralgic pain is not uncommon. Trigeminal neuralgia may appear in
patients with MS. The occurrence of trigeminal neuralgia in a person younger
than 40 is suggestive of MS. Lhermitte's sign (transient sensory symptoms
usually precipitated by neck flexion) is usually described as an electrical or
tingling sensation that travels down the spine or into the extremities.
Although quite common in MS, Lhermitte's sign can also occur with a wide
variety of other disorders, such as vitamin B12
deficiency, spondylosis, Chiari malformation, and tumors, and after cisplatin
chemotherapy. Several other paroxysmal symptoms are occasionally encountered,
including paroxysmal dysarthria and ataxia, paroxysmal dyskinesia/dystonias,
paroxysmal diplopia, and combinations of these symptoms. Facial myokymia and
hemifacial spasm are additional transient (lasting months) phenomena sometimes
due to brain stem demyelination.
Seizures occur in about 10 percent
of MS patients. Focal motor seizures, possibly with secondary generalization,
are the most frequent. The occurrence of seizures usually follow one of two
patterns. On occasion, focal onset seizures begin early in the course of MS and
later remit. The start of seizures late in the course of MS more often poses a
chronic problem and are frequently difficult to control.
MS is typified by multifocal CNS
involvement and acute relapses, remissions, and/or slow progression of
neurological deficits. A single episode of neurological dysfunction can be
suggestive of MS if it follows the typical time course of a relapse:
progression over less than 2 weeks (usually days), with or without a period of
stabilization, and improvement or resolution (often over months). Insidious
progression of deficits localized to a single site in the CNS can also be due
to MS, but other possible causes must be excluded. The temporal course of MS
can be described by one of four categories: relapsing/remitting (RR), secondary
progressive (SP), primary progressive (PP), and progressive relapsing (PR).а а
Other terms have been used in the
past to designate the course of MS, but because of the nonspecific terminology
and overlapping course descriptions they are no longer used. Many previous
clinical drug trials were performed in patients with a chronic progressive
course. It is difficult to interpret these data because patients with both PP
and SP MS were included and these patients may respond differently to
treatment. Many physicians use the term relapsing progressive, which
encompassed patients with SP, PR, and even those with RR MS who have stepwise
relapse-related worsening disability. This term has recently been abandoned.
Other terms that relate to the course of MS but have no consensus regarding
their definition are sometimes encountered. Benign MS generally refers
to patients who have had MS for a long period of time but yet have little or no
disability. Malignant MS is sometimes used to describe patients with
frequent relapses and incomplete recovery but is also used in reference to
patients with acute fulminant demyelinating syndromes (see later).
The eye is the only organ outside
the nervous system that is sometimes involved in MS. Uveitis and retinal
periphlebitis each occur in at least 10 percent of MS patients. The uveitis can
involve the posterior, intermediate (pars planitis), or rarely anterior portion
and resembles that seen in other inflammatory (e.g., sarcoid, Reiter's
syndrome, Behcyet's syndrome, inflammatory bowel disease, systemic lupus
erythematosus) and infectious (e.g., syphilis, tuberculosis, Lyme disease)
conditions. Periphlebitis is seen as venous sheathing on funduscopic
examination and is histologically identical to the perivascular inflammation present
in brain white matter. It is interesting that inflammation commonly occurs in
the retina, which has a peripheral type of myelin produced by Schwann cells.
There are occasional reports of
peripheral nerve or nerve root demyelination in MS patients as well as central
demyelination in acute inflammatory demyelinating polyradiculoneuropathy and
chronic inflammatory demyelinating polyradiculoneuropathy. Some of these cases
may be due to the incidental occurrence of two unrelated disease processes.
However, because the PNS and CNS share many antigens, including MBP, it is
possible that an autoimmune reaction or a viral infection could involve both
the CNS and PNS.
Persons with one autoimmune disorder
generally have an increased risk of others. Even though there are several
reports of systemic and organ-specific autoimmune diseases in MS patients,
population-based studies have not confirmed any increase in prevalence of these
disorders among MS patients. In fact, there appears to be a negative
association between MS and rheumatoid arthritis. No increased risk of brain
tumors or hematological malignancies have been found despite occasional
reported associations.
Differential
Diagnosis. There are few diseases that cause neurological
deficits, regress spontaneously, and relapse in different areas of the CNS over
the course of many years. However, because of the remarkable heterogeneity of
MS, many disorders may resemble MS), especially in the first years of active
disease.
Other primary idiopathic
inflammatory demyelinating CNS disorders may be mistaken for MS. Acute
disseminated encephalomyelitis (ADEM) usually causes monophasic CNS
demyelination. Although it frequently involves multifocal areas of white matter
near simultaneously, ADEM cannot always be reliably differentiated from the
initial clinical episode of MS. Fulminant brain demyelination in persons
without previous symptoms of MS is more likely due to ADEM or other conditions
(Schilder's myelinoclastic diffuse sclerosis, Balo's concentric sclerosis, Marburg's
variant of MS). Neuromyelitis optica differs from MS primarily in the
topography and intensity of the lesions.
Several systemic or organ-specific
inflammatory conditions can involve the CNS white matter. Optic neuritis,
myelitis, and other syndromes sometimes occur with systemic lupus
erythematosus. Whether this autoimmune disease increases the risk of developing
MS or causes similar syndromes by a different pathological process is unknown.
Sarcoidosis can affect the nervous system in several ways, including multifocal
corticosteroid-responsive white matter lesions. Sjogren's syndrome sometimes
occurs with MS, but this may only represent a chance association. Behcet's
disease has a predilection for the brain stem when it involves the CNS.
Occasionally, isolated demyelinating syndromes are associated with inflammatory
bowel disease.
A wide variety of vasculitic
syndromes (e.g., primary angiitis of the CNS, periarteritis nodosa, Wegener's
granulomatous angiitis, vasculitis associated with rheumatoid arthritis,
Susac's syndrome, Eales' disease) may mimic MS. However, these syndromes can
usually be distinguished by involvement of the cortex, seizures, early
dementia,
TABLE 48-3 -- DIFFERENTIAL DIAGNOSIS OF
MULTIPLE SCLEROSIS |
||
Other
inflammatory demyelinating CNS conditions |
Cerebrovascular
disorders |
|
Multiple
emboli |
|
|
Hypercoagulable
states |
|
|
Acute
disseminated encephalomyelitis |
Sneddons
syndrome |
|
Neoplasms |
|
|
Neuromyelitis
optica |
Metastasis |
|
Systemic
or organ-specific inflammatory diseases |
Lymphoma |
|
Paraneoplastic
syndromes |
|
|
Systemic
lupus erythematosus |
Metabolic
disorders |
|
Sjogrens
syndrome |
Vitamin B12 deficiency |
|
Behcets
disease |
Vitamin E
deficiency |
|
Inflammatory
bowel disease |
Central
(or extra) pontine myelinolysis |
|
Vasculitis |
|
|
Periarteritis
nodosa |
Leukodystrophies
(especially adrenomyeloneuropathy) |
|
Primary
CNS angiitis |
|
|
Susac's
syndrome |
Leber's
hereditary optic neuropathy |
|
Eales'
disease |
Structural
lesions |
|
Granulomatous
diseases |
Spinal
cord compression |
|
Sarcoidosis |
Chiari
malformation |
|
Wegener's
granulomatosis |
Syringomyelia/syringobulbia |
|
Infectious
disorders |
Foramen
magnum lesions |
|
Lyme
neuroborreliosis |
Spinal
arteriovenous malformation/dural fistula |
|
Syphilis |
|
|
HTLV-I
associated myelopathy |
Degenerative
diseases |
|
Hereditary
spastic paraparesis |
|
|
Viral myelitis
(HSV, VZV) |
Spinocerebellar
degeneration |
|
Progressive
multifocal leukoencephalitis |
Olivopontocerebellar
atrophy |
|
Psychiatric
disorders |
|
|
Subacute
sclerosing panencephalitis |
Conversion
reactions |
|
Malingering |
|
|
HTLV-I,
human T-cell lymphotropic virus type I; HSV, herpes simplex virus; VZV,
varicella-zoster virus; CNS, central nervous systen . |
|
personality changes, psychosis, infarcts involving large vessel territories on
MRI, and lack of improvement. Findings characteristic to the particular
vasculitis (uveitis and vitreal hemorrhage in Eales' disease; retinal and
cochlear involvement in Susac's syndrome; upper and lower respiratory tract
involvement in Wegener's granulomatosis) also aid in the correct diagnosis.
A few infections must also be
considered in the differential diagnosis of MS. Both Lyme disease and syphilis
may cause multifocal white matter lesions. HTLV-I causes a chronic progressive
myelopathy (HTLV-I-associated myelopathy/tropical spastic paraparesis). Acute
or recurrent myelitis can be caused by varicella-zoster virus or HSV.
Progressive multifocal leukoencephalopathy and Toxoplasma abscesses
should be considered in immunocompromised patients with progressive
neurological decline. Bacterial endocarditis with brain abscess formation, subacute
sclerosing panencephalitis, or chronic rubella encephalomyelitis may need to be
considered in the appropriate circumstances.
Cerebrovascular disease is only
rarely mistaken for MS. Occasionally, however, an MS relapse has an abrupt
onset that may mimic an infarct, especially in those not previously diagnosed
with MS. The usual circumstance is that of a hemisensory or hemimotor deficit
imitating a lacunar infarct. Disorders with multiple cerebral infarcts (emboli,
hypercoagulable states, Sneddon's syndrome, vasculitis) may produce an MRI
appearance and course resembling MS. Vascular malformations may also produce
symptoms similar to MS.
Additional neurological illnesses
capable of producing multifocal lesions rarely manifest similar to MS.
Metastatic tumors and multifocal gliomas have been reported as being suggestive
of MS, but this must be considered extraordinarily rare. Lymphoma more commonly
masquerades as MS because the lesions may involve the white matter, may be
multifocal, and are corticosteroid responsive. In addition, demyelination
sometimes presents as one (or a few) mass lesion(s). In this situation, biopsy
may be needed for diagnosis. Neoplasms can cause paraneoplastic syndromes that
may be confused with MS. A high index of suspicion must be kept for older age
at presentation, subacute ataxia, early dementia, and personality changes.
A few metabolic disorders may
resemble MS such as vitamin B12
deficiency, vitamin E deficiency (seen in Bassen-Kornzweig syndrome,
hypobetalipoproteinemia, and Refsum's disease), and central pontine or
extrapontine myelinolysis. Leukodystrophies are usually not difficult to
distinguish from MS. Krabbe's disease (galactocerebroside-beta-galactosidase
deficiency), metachromatic leukodystrophy (arylsulfatase A deficiency), and the
usual adult form of adrenoleukodystrophy (ALD) and adrenomyeloneuropathy (AMN)
exhibit both central and peripheral dysmyelination. Blood leukocyte or
fibroblast culture enzyme activity levels will confirm the diagnosis of
Krabbe's disease and MLD, and elevated levels of very long chain fatty acids
occur in ALD/AMN. Mitochondrial disorders should also be given consideration
because symptoms and MRI appearance may be similar to MS. A relapsing remitting
disorder identical to MS is sometimes seen in patients with the mutations
responsible for Leber's hereditary optic neuritis. This
usually occurs in female patients, and there may not be a family history of
visual loss. A number of rare biochemically defined illnesses and other genetic
disorders may occasionally merit consideration (including cobalamin and folate
dysmetabolism, adult polyglucosan body disease, hereditary spastic paraparesis,
spinocerebellar degeneration, and hereditary cerebroretinal vasculopathy).
Several additional disorders must be
excluded before diagnosing primary progressive MS. Spinal cord compression from
spondylosis or tumor may produce chronic progressive myelopathy. Chiari
malformations, syringomyelia, syringobulbia, other foramen magnum lesions,
spinal arteriovenous malformations, and dural fistulas may also need
consideration. These structural abnormalities are readily identified by
imaging. Degenerative diseases such as olivopontocerebellar atrophy may mimic
PP MS. MRI and CSF examination will help distinguish between the two.
When clinical and paraclinical
findings are absent among a multitude of complaints or when apparent severe
loss of function, without clinical evidence of neurological disease, is faced
with a lack of concern, it may be appropriate to consider psychiatric disorders
such as somatization, malingering, or conversion reactions.
Evaluation. The
diagnosis of MS is based on the demonstration of white matter lesions
disseminated in time and space in the absence of another identifiable
explanation. MS remains a clinical diagnosis, although MRI, evoked potentials,
and CSF examination can help clarify less certain cases. For research purposes,
various categories of MS have been defined based on the certainty of the
diagnosis. At least two attacks and evidence of two separate CNS
lesions
(clinical or paraclinical) are required for the designation of clinically
definite MS (CD MS). Two attacks and evidence for one or one attack and
evidence of two CNS lesions (clinical or paraclinical) is considered clinically
probable MS. Cases that fulfill the criteria for clinically probable MS and
have supportive CSF findings are labeled as laboratory-supported definite MS.
Patients with a clear history of at least two attacks and supportive CSF but a
normal neurological examination and no paraclinical evidence of CNS lesions are
categorized as having laboratory-supported probable MS. Suspected cases
that do not fit any of these criteria may be regarded as possible MS.
Paraclinical evidence generally refers to abnormalities on evoked potential
studies or imaging procedures, but urological studies and hot bath tests can
also be used. To exclude the simultaneous development of lesions, as in ADEM,
when using paraclinical evidence in patients with only one attack it must be
known that the studies were normal at the time of that attack or, in the case
of MRI, that new lesions have developed. The presence of both enhancing and
nonenhancing white matter lesions on a single MR image must not be used as
evidence of dissemination in time as well as space, because these can also be
seen in ADEM. The presence of oligoclonal bands (OCBs) and an elevated IgG
index or synthesis rate provide supportive CSF findings.
Ancillary tests are frequently
required to confirm the diagnosis of MS and to exclude other possibilities.
Laboratory tests on peripheral blood can help to exclude many of the infectious
and other inflammatory disorders. A chest radiograph is generally needed to
assess for sarcoid or paraneoplastic disorders if these are under consideration.
An ophthalmological examination may be needed to search for alternate causes of
visual loss. Imaging studies, CSF examination, and evoked potentials are often
helpful because characteristic abnormalities are frequently present.
MRI of the head is the most
sensitive study for MS and
is far more
useful than computed tomography (CT). Eighty-five to 95 percent of CD MS
patients have abnormalities on head MRI. Focal areas of increased T2-weighted
and decreased T1-weighted signal reflect the increased water content associated
with demyelinated plaques. The MRI appearance of MS lesions, however, is not
specific and similar abnormalities may be seen in normal aging, small
penetrating vessel infarcts, Lyme disease, tropical spastic paraparesis/HTLV-I
associated myelopathy (TSP/HAM), sarcoid, systemic lupus erythematosus,
Sjogren's syndrome, mitochondrial cytopathies, vasculitis, and ADEM. The
specificity for MS can be increased by consideration of lesion number, size,
location, and shape. This is especially important in persons older than 50. MRI
characteristics that are strongly suggestive of MS include multiple lesions
(more than three), size larger than 6 mm, oval shape (often with the long axis
directed perpendicular to lateral ventricles), and locations in the
periventricular area, corpus callosum, and posterior fossa.
Longitudinal MRI studies have shown
the evolution of MS lesions. Gadolinium enhancement, indicating blood-brain
barrier disruption, sometimes precedes the development of T2-weighted lesions
and lasts for 2 to 4 weeks. The new T2-weighted lesion has a fuzzy border and
enlarges over a few weeks. After a period of stabilization, the T2-weighted
lesion regresses and becomes more sharply delineated from the surrounding white
matter as edema resolves. Most of the time, a residual abnormality with
increased T2 weighting and decreased T1-weighted signal remains, reflecting
demyelination and gliosis. The MRI activity of disease, defined as either the
number of new, recurrent, and enlarging lesions or the number of
gadolinium-enhancing lesions, is much higher than the clinical activity. This
may be either because of the involvement of asymptomatic areas of the CNS or
because of a pathophysiological difference between symptomatic and
nonsymptomatic lesions based on the presence or absence of axonal dysfunction.
There is only a poor correlation
between disability and lesion load (volume of white matter abnormalities)
determined by head MRI. Sometimes individuals have severe impairment and few
abnormalities, and the converse may occur. This disparity is partially
explained by variable spinal cord involvement, but a pathophysiological
difference may account for some of the discrepancy.
MRI has become an important
component of recent clinical trials. Because of the high sensitivity of MRI for
disease activity, it is reasoned that periodic MRI can determine treatment
efficacy much more quickly than monitoring relapse rate or disability level.
Many studies have used MRI as a secondary outcome, and a few have used it as a
primary outcome, a true surrogate marker of the main parameter of interest.
Additional MRI techniques have also
proven useful in the diagnosis of MS. MRI of the spinal cord shows discrete
lesions in about 80 percent of CD MS patients. Fluid attenuated inversion
recovery eliminates the CSF signal from T2-weighted images and increases the
contrast of lesions and sensitivity of both head and spine MRI. Short
time-inversion recovery suppresses fat signal and is useful in detecting optic
nerve lesions. Magnetization transfer imaging takes advantage of the
macromolecular environment of protons and can discern early edematous lesions,
which are frequently reversible, from chronic demyelinated and gliotic lesions
that are nonreversible. MR spectroscopy is used to determine the biochemical
changes that occur in lesional and nonlesional white matter of MS patients.
CSF evaluation remains a valuable
diagnostic tool for MS. A lymphocytic pleocytosis occurs during acute
exacerbations in about one third of patients, but this seldom
exceeds 50
cells. Total protein is often mildly elevated, and the proportion of
gamma-globulin is high owing to the synthesis of immunoglobulins within the
blood-brain barrier. The majority of CSF immunoglobulin is IgG, although IgM and
IgA may also be elevated. Measures of intrathecal IgG production have been
devised that are more useful than simple gamma-globulin levels. The IgG index
and synthesis rate are elevated in 70 to 90 percent of CD MS patients and
occasionally in other disorders (see later). Agarose gel electrophoresis, or
the more sensitive isoelectric focusing of CSF proteins, often reveals discrete
bands of immunoglobulin, each a monoclonal antibody. It is pertinent to compare
serum and CSF banding patterns because peripheral monoclonal gammopathies may
produce CSF bands. To reduce false-positive results, only unique CSF OCBs
should be reported. Between 85 and 95 percent of CD MS patients have OCBs;
however, early in the course they are not as prevalent. Once present, OCBs persist
and the pattern does not vary, although new bands occasionally appear. Unlike
subacute sclerosing panencephalitis, in which the majority of OCBs are
antibodies specific for measles virus, the specificity of OCBs in MS is
unknown.
The presence of OCBs does not
necessarily imply MS, because up to 8 percent of non-MS CSF samples contain
them.Other inflammatory or infectious illnesses are usually responsible for
OCBs in non-MS patients, and in these instances they often do not persist. The
presence of myelin components, antimyelin antibodies, and kappa light chains in
CSF has also been used in the diagnosis of MS. However, the sensitivity and
specificity of these products is less than that of OCBs.
Evoked potentials are summed
cortical electrical responses to peripheral sensory stimulation that can be
used to localize sites of pathology and measure conduction velocity along
sensory pathways. Visual evoked potentials (VEP) and somatosensory evoked
potentials (SSEP) may detect subclinical sites of demyelination, thus providing
evidence of multifocality. Brain stem auditory evoked potentials (BAEP) are
occasionally informative. More than 90 percent of persons with a history of
optic neuritis have an abnormal VEP, and 85 percent of CD MS patients have
abnormalities on VEPs even when the history of optic neuritis is absent. Slowed
conduction is present on SSEP in nearly three fourths of patients with CD MS.
BAEPs are the least sensitive, with abnormalities in approximately 50 percent.
MRI has largely supplanted the use of evoked potentials in MS because of the
greater sensitivity in the diagnosis and the detailed anatomical information it
provides.
Management. There
is no available prevention or cure for MS. Yet a number of therapies may hasten
recovery from exacerbations, provide symptomatic relief of symptoms, maximize
physical abilities, and prevent certain complications. In addition, treatments
that alter the natural course of MS have become available and others are being
developed. Methods of enhancing recovery are also being explored.
Acute
Exacerbations. Corticosteroids are the most commonly used treatment
for MS, although there have been few studies to address their efficacy.
Adrenocorticotropic hormone (ACTH) was shown to speed recovery from an
exacerbation but had no effect on the ultimate degree of recovery. Because of
the unpredictable cortisone response to ACTH, oral prednisone and later
intravenous methylprednisolone became the preferred treatments. The Optic
Neuritis Treatment Trial verified that intravenous methylprednisolone but not
prednisone increased the recovery rate and unexpectedly increased the time to
the next relapse, thus delaying the diagnosis of CD MS.Moreover, the
prednisone-treated group had twice as many recurrences. The reason for this
unconfirmed finding and its relevance to those with definite MS are unknown.
Nonetheless, it has affected the practice of treating acute MS exacerbations.
The current recommendation is to treat disabling attacks with 500 to 1000 mg of
intravenous methylprednisolone per day for 3 to 5 days with or without a short
tapering dose of oral corticosteroids.
Because up to one third of patients
do not have adequate recovery after a relapse despite the use of
corticosteroids, other therapies are needed. Unfortunately, the only additional
controlled clinical study to address this evaluated the combination of
simultaneous ACTH and cyclophosphamide with true or sham plasma exchange.а аAlthough the group treated with plasma
exchange was thought to recover faster, the benefit was marginal at best and
this treatment program has found no clinical utility. Plasma exchange alone was
found beneficial in some patients with severe inflammatory demyelinating
episodes who had failed to improve with intravenous therapy with methylprednisolone,
and a double-blind crossover study is in progress to confirm this finding.
Alteration of the
Natural Course. The primary goal of drug treatment is to alter the
natural course of the disease. In MS clinical trials, this means reduction in
the frequency and severity of relapses, preventing the chronic progressive
phase, and slowing the progression of disability. The activity of disease seen
on MRI is often used as a secondary outcome. Many different immunosuppressive
and immunomodulating therapies have been evaluated, and several other studies
are in progress.
Cyclophosphamide is an alkylating
agent that has indiscriminant cytotoxic effects on rapidly dividing cells,
including lymphocytes, making it a potent immunosuppressant. Several studies
have claimed a beneficial effect in both relapsing and progressive patients.
Because one of the major studies included ACTH, intravenous methylprednisolone
is sometimes given with the cyclophosphamide. Other trials have not found a
favorable effect. Because of the inconsistent results, high potential for
serious side effects, and adverse reactions, including hemorrhagic cystitis and
malignancy, cyclophosphamide is not widely used. Some centers, however, use
cyclophosphamide in patients with aggressive disease in whom more conventional
treatments have failed.
Numerous studies have shown
azathioprine, a purine analog antimetabolite, to have marginal efficacy in the
treatment of MS. A meta-analysis of all blind, placebo-controlled studies
confirmed a slight benefit of slowed progression and less frequent relapses.
The toxicity of azathioprine and its slow onset of action have prevented its
widespread use. Besides the liver toxicity and hematological effects, the
induction of malignancies has been a concern. One retrospective study did not
find an increased incidence of cancer in MS patients treated with azathioprine,
but this remains a potential risk.
Methotrexate is a folate antagonist
that is effective in rheumatoid arthritis. Weekly low-dose oral methotrexate was
found to delay upper extremity dysfunction in SP MS patients, although it had
no effect on the more traditional measures of disability, including the
Expanded Disability Status Scale (EDSS)
The use of cyclosporine in the
treatment of MS has been evaluated in three clinical trials, none of which have
demonstrated a convincing benefit. In addition, side effects such as
hypertension and elevation of creatinine were fairly common. Cladrabine is a
nucleoside derivative that was found to decrease relapse rate and slow the
progression in patients with SP MS in an initial investigation. Although
cladrabine was administered intravenously through a surgically implanted
central venous line in that study, a large clinical trial is being done to
determine whether the drug is effective when administered subcutaneously. The
drug is better tolerated than other parenteral immunosuppressants, although
bone marrow suppression is a risk.
Interferons are a class of peptides
that have antiviral and immunoregulatory functions. A pilot study of
interferon-gamma in MS was aborted after an increased exacerbation rate was
noted. In retrospect, this was not surprising because it is now known to be a
proinflammatory, TH1-related cytokine that acts in part by increasing HLA type
II expression. Interferon-alfa and interferon-beta have similar physiological
actions and are part of the anti-inflammatory TH2 response. Interferon-beta 1b
(Betaseron) was the first drug approved by the U.S. Food and Drug
Administration (FDA) specifically for the treatment of MS. A large clinical
study in RR MS patients demonstrated a reduction in the frequency of relapses
by about one third with subcutaneous injection every other day. The severity of relapses was also lessened. Perhaps
the most striking observation was its effect on MRI. The placebo-controlled
group continued to accumulate white matter lesions, whereas patients in the
high dose arm (8 million IU) had stabilization of their MRI and did not
accumulate higher lesional volumes. No difference was found in the disability
levels, however. Patients on a low dose of interferon-beta 1b actually did
worse than placebo-treated patients on clinical measures, although there was a
favorable effect on MRI behavior. This observation remains unexplained.
Interferon-beta 1b is being further investigated in SP MS patients. Side
effects include injection site reactions, flulike symptoms (low-grade fever,
myalgias, headache; these lessen in frequency after treatment for a few
months), mild liver enzyme elevation, and lymphopenia. Depression and attempted
suicide were more common in the treated groups. One particularly disturbing
result was the production of neutralizing autoantibodies in 38 percent of
patients after 3 years of treatment. Not only do patients with these antibodies
thereafter fail to respond to this drug, but there is also a concern that
neutralizing antibodies may cross react with natural interferon-beta and
interfere with its function. The long-term effects of these antibodies are
unknown.
Another formulation of
interferon-beta has been approved by the FDA. Interferon-beta 1a (Avonex) has
the same amino acid sequence as natural interferon-beta and differs from
interferon-beta 1b by one amino acid as well as by the presence of carbohydrate
moieties. Once-weekly intramuscular interferon-beta 1a has been found to have
effects similar to that of interferon-beta 1b in reducing the frequency of MS
relapses. In addition, a favorable effect on disability was also demonstrated
and side effects were less common. Neutralizing antibodies occurred half as
often as with interferon-beta 1b. MRIs showed less enhancing lesions in the
treated group but no difference in the change of lesional volume after 2 years.
Duration of follow-up was, however, much less in the interferon-beta 1a study
than in the interferon-beta 1b trial.
Copolymer 1 is a synthetic mixture
of polypeptides produced by the random combinations of four amino acids that
are frequent in MBP. After a preliminary study suggested efficacy, a
randomized, double-blind, placebo-controlled, multicenter trial showed a 29
percent reduction in relapse rate and a mild positive effect on disability in
RR MS patients. No MRI data have been presented.
Numerous additional therapies have
been tested, and many others are undergoing evaluation. The antiherpesvirus
drug acyclovir has been shown to reduce relapse frequency in a small
prospective trial. Total lymphoid irradiation was found to slow the chronic
progression of MS; but because this approach precludes the later initiation of
immunosuppressant drugs and may be associated with a higher mortality rate, it
is not widely used. Results of the initial small study of the immunosuppressant
drug mitoxantrone seemed promising, but subsequent studies have found only
modest effects. Monthly treatment with intravenous immunoglobulin in RR MS
patients resulted in fewer and less severe relapses in addition to slowing the
accumulation of disability in one small study. A unique mechanism of action is
being explored with the use of oral myelin in a large phase III clinical trial.
This trial tests the hypothesis that the oral administration of antigen may
induce tolerance through either active suppression or anergy/ deletion.
Vaccination with CD52, CD4, irradiated MBP-specific CD4 cells, TCR variable
beta 6, and variable beta 5.2 are under investigation in MS patients.
Additional ongoing studies are investigating the potential role of
sulfa-salazine and tacrolimus.
Symptomatic
Treatment. Spasticity is common even in patients with only
minimal weakness. It is usually prudent to begin treatment of mild spasticity
with a stretching program. The addition of an evening dose of benzodiazepine
may help relieve extensor spasms and clonus that may interfere with sleep. As
spasticity worsens it becomes necessary to use baclofen. Doses should be
escalated slowly to prevent the occurrence of overt side effects, and up to 120
mg/day may be required. Although baclofen is well tolerated in most patients,
limiting side effects such as sedation and increased muscle weakness occur, and
rarely a paradoxical increase in spasticity is noted. Liver enzyme elevation
and nonconvulsive status epilepticus presenting as encephalopathy have also
been reported in association with baclofen. Abrupt withdrawal of baclofen may
result in hallucinations or seizures, making it necessary to taper doses.
Despite symptomatic improvement, antispasticity measures may not increase
function or independence. In paraplegic patients with severe spasticity and
intolerance to the required oral dose, intrathecal baclofen delivered by a
subcutaneously implanted pump allows a much smaller dose and is often effective
in alleviating intractable spasticity and may lessen urinary urgency.
Tizanidine seems to be as effective as baclofen. Dantrolene has been used for
spasticity, although the therapeutic window is small.
The treatment of fatigue is far from
optimal, and medications are only partially effective. Amantadine at 100 mg
twice per day is the standard initial treatment, although pemoline 37.5 mg daily
is also superior to placebo. The stimulating effects of the selective serotonin
reuptake inhibitors may also be somewhat effective in combating MS-related
fatigue. Often, however, patients need to limit activities and schedule rest
periods. Similarly, emotional incontinence may be amenable to a low dose of a
tricyclic antidepressant.
Paroxysmal symptoms are highly
responsive to medical treatment. A small dose of carbamazepine is often very
effective. If not tolerated, several alternative medications may be tried,
including phenytoin, acetazolamide, baclofen, and gabapentin. In addition,
misoprostol has been claimed to be effective in MS-related trigeminal
neuralgia. After about 1 month of treatment, periodic attempts at tapering off
these medications is a reasonable approach because these symptoms usually
remit. Seizures are treated no differently than in non-MS conditions. Heat
sensitivity may require avoidance of precipitating activities, but this depends
on the nature of symptoms and the situation in which they occur. If the
precipitating activity cannot be avoided, a cooling jacket may be an option. A
potassium channel blocker, 4-aminopyridine improves temperature sensitivity in
some patients but occasionally causes seizures or disturbing paresthesias.
Action tremor is a common disabling symptom. Unfortunately, it is often only
marginally amenable to medical therapy. Clonazepam may afford some relief, but
tolerance frequently develops, necessitating increasing doses. Isoniazid and
carbamazepine have also been found marginally beneficial. One clinical trial
showed ondansetron to reduce tremor-related disability. Anecdotal reports
suggest that gabapentin may be partially effective. Improvements in
stereotactic neurosurgery have made thalamotomy a legitimate option in those
whose disability is mainly due to tremor and not ataxia.
Dysesthetic pains are difficult to
control but sometimes respond to tricyclic antidepressants, carbamazepine, or
baclofen. Gabapentin and tramadone may also be effective. Standard analgesics
are not often useful in MS-associated pain, and narcotics should be avoided in
the treatment of chronic pain.
Symptoms of a hyperreflexic bladder
(urgency, frequency, and urge incontinence) are often manageable with
anticholinergics such as oxybutynin, propantheline, or imipramine. A flaccid
bladder can sometimes be aided by bethanechol, although intermittent
catheterization is more often needed. Symptoms that suggest urinary retention
(a feeling of incomplete emptying, frequency, hesitancy, or a need to apply
pressure to the lower abdomen to urinate) should prompt evaluation with
urinalysis and a post-void residual urine measurement. Residuals in excess of
15 ml are abnormal; and if they are above 50 ml, consideration should be given
to urological consultation for more thorough investigation and to blood
chemistries to determine urea and creatinine levels. Detrusor-sphincter
dyssynergia, diagnosed by cystometrography, is treated with anticholinergics,
sometimes with the addition of an alpha-1 blocking agent (terazosinа Hytrin ) or intermittent catheterization. It
is important to reassess bladder function periodically, and residuals should be
monitored if there are any persistent changes in function or symptoms.
Intermittent catheterization should be considered when post-void residuals
reach 100 ml. A chronic indwelling urinary catheter should be avoided if
reasonably possible. It is usually not necessary to use antibiotics
prophylactically in the prevention of urinary tract infections. Urinary calculi
may be prevented by acidification of the urine with cranberry juice.
Constipation can usually be managed with bulk laxatives and stool softeners.
More severe cases may require osmotic agents, bowel stimulants, anal
stimulation, suppositories, or enemas. Bedridden patients may develop fecal
impaction unresponsive to these measures and require manual disimpaction. Fecal
incontinence can be minimized by adherence to a schedule for bowel movements.
It is pertinent to determine the
precise nature of any sexual dysfunction in patients with MS. Physical
difficulty from spasticity may be alleviated by premedication with baclofen,
and a fast-acting anticholinergic such as oxybutynin may calm urinary urgency.
Sexual dysfunction should not be automatically attributed to MS. It may be
necessary to investigate hormonal levels and to obtain urological or
gynecological consultation. Manual lubrication with gel is a ready solution to
vaginal dryness. Erectile dysfunction may be treated by vacuum devices,
intracavernous injections of papaverine (or combinations of papaverine,
prostaglandins, and epinephrine; triple agent), or penile implant.
It is advisable for MS patients to
attain good health habits, including proper diet and fitness. Smoking, excess
alcohol, and obesity should be avoided. Exercise can help maximize function by
increasing and maintaining joint mobility, strength, and stamina. This may in
addition promote fitful sleep and possibly reduce the impact of fatigue.
Physical and occupational therapy can play an important role in regaining
independence. Canes, walkers, and wheelchairs or scooters may be needed to
maintain safe mobility. Hand controls can be installed in automobiles for
patients with lower extremity dysfunction. In debilitated, immobilized patients,
periodic shifts in posture to change weight-bearing regions and air or water
mattresses prevent bed sores. Passive range of motion exercises prevent
contractures.
Enhancement of
Recovery. The exact reason for persistent neurological deficits
in MS is unknown. Primary demyelination, axonal dysfunction, extensive gliosis,
or axonal loss may all contribute. In the past it was thought that the CNS had
no potential for remyelination. Pathological studies have suggested that
limited remyelination does occur but is arrested for unknown reasons.
Immunization with spinal cord homogenate was found to markedly enhanced central
remyelination in an EAE model. Using the TMEV model (confirmed in EAE),
Rodriguez identified two monoclonal autoantibodies that promote CNS remyelination. A preliminary study based on these studies found that
intravenous immunoglobulin (IVIG) improved vision and VEP latencies in some MS
patients with presumably permanent visual impairment. Currently phase II trials are being done to determine
if IVIG treatment can lead to functional improvement in patients with
apparently irreversible weakness or optic nerve dysfunction.
Pregnancy.
Before initiation of any drug in a woman of reproductive age, the potential for
teratogenicity must be discussed. The treatment of acute exacerbations is
unchanged during pregnancy, although one might have a higher threshold for
treatment. Both corticosteroids and plasma exchange are relatively safe to use
during pregnancy. None of the drugs used to alter the disease course, however,
should be used during pregnancy, and they should be stopped if pregnancy
occurs. The cytotoxic immunosuppressants have teratogenic effects, and
interferon-beta induces spontaneous abortion in animals. The effects of many of
the other drugs are unknown. It is best if these drugs are stopped several
months before a planned pregnancy.
Prognosis and
Future Perspectives. Because most information on the prognosis of MS is
reported in terms of the EDSS, it is important to have some understanding of this
scale. The EDSS is a 10-point scale with each increase representing worsening
symptoms or function. The score is derived from severity scores in each of six
systems as well as ambulation and work ability. A score of 0 means no signs or
symptoms; 1 to 3 represent mild disability with no or minimal impairment of
ambulation; 3.5 to 5.5 refer to moderate disability and impairment of gait; the
need for a cane to walk one-half block (100 m) marks a score of 6; an EDSS of 8
refers to the need for a wheelchair and effective upper extremity function; an
EDSS of 10 refers to death related to MS.
MS has a highly variable outcome,
ranging from asymptomatic to fulminant with death ensuing in a matter of
months. Autopsy series have estimated that unsuspected MS may occur in as many
as 0.2 percent of the population. Even when symptomatic, MS may cause only
nuisance symptoms. Benign MS, when defined as unrestricted ambulation or EDSS
of 3 or less 10 years after onset, accounts for about one third of cases.
However, many of these patients acquire more disability at a later time. When
considering all patients with MS, Weinshenker found that 15 years after onset,
80 percent had EDSS worse than 3, 50 percent had reached EDSS of 6 or more, 10
percent were at EDSS 8, and 2 percent had died. The percentage of patients with
initially RR MS who develop SP MS increases steadily with disease duration. At
10 years, 40 to 50 percent have continual deterioration; and after 25 years,
approximately 80 percent have slow progression.
Natural history studies have
identified several prognostic indicators that predict outcome to a limited
extent. Factors associated with a better prognosis (slower accumulation of
disability, longer time before chronic progression) include young age at onset,
female gender, RR course (as opposed to PP MS), initial symptoms of sensory
impairment or optic neuritis, first manifestations affecting only one CNS
region, high degree of recovery from initial bout, longer interval between
first and second relapse, low number of relapses in the first 2 years, and less
disability at 5 years after onset (both EDSS and number of systems
affected--sensory, motor, sphincter, brain stem, vision, cerebral). Despite the
indolent nature, a PP course is the worst prognostic factor, with the median
time to reach EDSS 6 of only 6 years, compared with approximately 20 years in
RR patients. Men and patients with an older age at onset are more likely to
have PP MS.
The survival of MS patients is only
slightly below expected. Seventy-six percent of patients are alive 25 years
after onset, which is 85 percent of that seen in age- and sex-matched controls.а аMS is rarely the direct cause of death,
although respiratory failure from cervical myelopathy or extensive cerebral and
brain stem demyelination and death occasionally occurs with acute or subacute
exacerbations. Complications of
MS such as pneumonia, pulmonary emboli, aspiration, urosepsis, and decubiti are
responsible for 50 percent of deaths. Most of the other deaths are from heart
disease, cancer, cerebrovascular disease, and trauma. Suicide is the only cause
of death that is overrepresented among these cases. The suicide rate among MS
patients may be as high as two to seven times that of non-MS persons.
The next decade may bring further delineation
of susceptibility genes and possibly the mechanism by which they exert their
actions. The virology of MS, including the possible role of human herpesvirus
6, will likely be further clarified. Persistence of additional viruses within
the CNS may be discovered, adding complexity to this situation.
It seems clear that global
immunosuppression is only marginally effective. Current studies concentrate on
immune modulation by inhibiting or augmenting certain aspects of the immune
response. The strategies employed include the following: induction of tolerance
to MBP and other myelin components; reduction of T-cell subsets by the use of
monoclonal antibodies, vaccination, or drugs; administration of
anti-inflammatory (TH2) cytokines; inhibition of proinflammatory (TH1)
cytokines; and blocking the trafficking of activated lymphocytes into the CNS.
Neuromyelitis optica (NMO) is an
uncommon neurological illness characterized by the occurrence of optic
neuropathy and myelopathy in close temporal relationship. The separation from
MS has become questioned, owing to the frequent dissemination of lesions
outside the optic nerves and spinal cord. Part of the difficulty lies with the
broad, imprecise, and inconsistent definition. The names Devic's syndrome,
Devic's disease, and NMO are often used interchangeably, although the first
name encompasses all patients who fit the above definition and the second and
third should only be used to refer to those patients presumed to have a
distinct disorder. The term opticospinal MS is often used in the Far
East to denote patients with exclusive or predominant involvement of optic
nerves and spinal cord, encompassing most patients with Devic's syndrome.
Pathogenesis and
Pathophysiology. Devic's syndrome may occur with ADEM, autoimmune
disorders, MS, and possibly viral infections. Not surprisingly, the
pathological descriptions are quite varied because these patients are
invariably a heterogeneous group. Classically, acute spinal cord lesions
demonstrate diffuse swelling and softening that extend over several levels or
involve nearly the entire cord in a continuous or patchy distribution. Acutely,
there is destruction with dense macrophage infiltration involving white and
gray matter, loss of myelin and axons, and lymphocytic cuffing of vessels. In
chronic lesions, the cord is atrophic and necrotic, with cystic degeneration
and gliosis. In the absence of perivascular cuffing, these extensive lesions
resemble infarctions. The prominent spinal cord swelling in the confines of the
restrictive pia presumably may raise intramedullary pressure, leading to the
collapse of small parenchymal vessels, further propagating tissue injury.
Proliferation of vessels with thickened and hyalinized walls similar to that
seen after infarction or other extensive injury may occur.а аLess fulminant lesions commonly coexist and
are much more typical of inflammatory demyelination. The optic nerves, chiasm,
and occasionally cerebral hemispheres are involved in a similar fashion with
either demyelinating lesions, necrotizing lesions, or both.
Epidemiology and
Risk Factors. Devic's syndrome occurs in patients of varied ages
(range, 1 to 73). The mean age at onset of monophasic Devic's syndrome is 27,
whereas relapsing NMO (see later) tends to occur in an older age group (mean
age at onset of 43). Monophasic Devic's syndrome affects males and females
equally, whereas relapsing NMO affects females predominantly (F:M, 3.8:1). One
third of patients have a preceding infection within a few weeks of neurological
symptom onset. Most commonly this is a nonspecific upper respiratory tract
infection, flu, or gastroenteritis. The most common specific infections
preceding the development of Devic's syndrome are chickenpox and pulmonary
tuberculosis. Devic's syndrome has also followed vaccination for swine flu and
mumps. Only a few instances of the familial occurrence of Devic's syndrome have
been reported, and in one of these families a unique mitochondrial mutation was
found. Devic's syndrome is said to be more common in Japan and East Asia,
although even there it is uncommon (less than 5 per 100,000).
Clinical Features
and Associated Findings. Symptoms of optic neuritis and myelitis develop over
hours to days and are often preceded or accompanied by headache, nausea,
somnolence, fever, or myalgias. Continued progression of symptoms over weeks or
months occasionally occurs. Most patients (greater than 80 percent) develop
bilateral optic neuritis. Bitemporal or junctional field deficits, indicating
chiasm involvement, are sometimes present early in the course of the optic
neuritis. Visual loss is often accompanied by periocular pain, and myelitis
onset is sometimes heralded by localized back or radicular pain. Lhermitte's
sign is common. Severe degrees of neurological deficits are usual, and the
degree of recovery is variable.
Patients who present with Devic's
syndrome can follow one of several possible courses. Approximately 35 percent
have a monophasic illness, 55 percent develop relapses nearly limited to the
optic nerves and spinal cord (relapsing NMO or opticospinal MS), and rarely
patients have a fulminantly progressive course without relapses or a course
typical of MS.а
аRelapsing NMO
is often associated with autoimmune disorders, most commonly systemic lupus
erythematosus. These patients also frequently have an elevated erythrocyte
sedimentation rate and nonspecific elevation of autoantibodies, including
antinuclear antibodies, anti-dsDNA, and antiphospholipid antibodies. Tonic spasms
and neuropathic lower extremity pain are common sequelae to the spinal cord
damage. Symptoms referable to brain stem lesions (nystagmus, ophthalmoparesis,
vertigo) can occur in these patients as well.
Differential
Diagnosis. The differential diagnoses for Devic's syndrome
includes MS, ADEM, pulmonary tuberculosis, and viral infection (especially in
the immunocompromised patient). In patients with an apparent affected family
member, consideration should be given to mitochondrial disease. Relapsing NMO
should raise the suspicion for associated autoimmune disorders. Because Devic's
syndrome can occur in persons older than the age of 60, when an unrelated
ischemic optic neuropathy could occur, and because isolated or recurrent
myelopathy may precede the optic neuritis, additional consideration must be
given to spinal cord compression, spinal cord tumor, and spinal arteriovascular
malformation or dural fistula.
Evaluation.
Imaging is needed to exclude structural lesions and provide information on the
pathological process. Optic nerve or chiasm enlargement, T2-weighted signal
changes, and enhancement may be seen on head MRI during the acute phase.
Increased T2-weighted signal in the medulla is not uncommon and usually
represents extension of high cervical lesions. Cerebral white matter lesions
can be seen on head MRI in about 25 percent of cases. Spine MRI
characteristically shows cord swelling, signal changes, and enhancement
extending over several levels. This appearance may resemble a spinal cord
tumor, prompting consideration for biopsy. An occasional patient may need prone
and supine myelography to exclude a spinal dural-based AVM. Laboratory
investigations reveal an elevated erythrocyte sedimentation rate in one third,
positive antinuclear antibodies in nearly one half, and occasionally other
autoantibodies.а
аIt is
reasonable to exclude syphilis, Lyme disease, and human immunodeficiency virus
by laboratory testing. A chest radiograph helps to exclude pulmonary
tuberculosis and sarcoidosis. CSF examination is an essential part of the
evaluation for Devic's syndrome, and repeated studies are sometimes necessary
to ensure that there is no infection in that the CSF findings are sometimes
atypical for inflammatory demyelination. In contrast to MS, a minority of
patients with Devic's syndrome (17 percent) have a normocellular CSF during the
acute phase. A marked pleocytosis is often present, sometimes exceeding 100
cells. Moreover, neutrophils are commonly seen in CSF and may predominate, a
situation virtually unknown in MS.а а, аааThe protein concentration is often very high
and in 41 percent exceeds 100 mg/dl. Despite the intense inflammatory response,
OCBs are conspicuously absent in the majority, being present in fewer than 20
percent of patients. CSF serology for the herpesvirus family (HSV types 1 and
2, varicella-zoster virus, Epstein-Barr virus, and cytomegaloviruses) is
important, and polymerase chain reaction testing should be done in cases
suggestive of viral infection (immunocompromised patients).
Management.
Patients with acute or subacute Devic's syndrome often respond to
corticosteroids (e.g., intravenous methylprednisolone). Limited experience
suggest that they may respond to plasma exchange even when intravenous
methylprednisolone does not produce significant improvement. Attempts at
preventing relapses and the subsequent disability are often disappointing even
with the use of immunosuppressive agents (e.g., azathioprine,
cyclophosphamide).
Supportive care is a mainstay of
management. Patients with Devic's syndrome are prone to many complications and
require measures to prevent deep venous thrombosis and pulmonary embolism,
urinary tract infection, decubiti, and contractures. Mechanical ventilation may
be needed either temporarily or permanently. Patients with monophasic Devic's
syndrome generally have simultaneous or rapid onset of the optic neuritis and
myelitis (interval usually less than 1 month). Although some have significant
residual disability, many recover remarkably and have little or no permanent
deficits. A history of previous vague neurological symptoms or definite
demyelinating events is predictive of future relapses, either typical of MS or
relapsing NMO. Those patients destined for recurrent myelitis and optic
neuritis have a longer interval between the onsets of myelitis and optic
neuritis. The vast majority of patients with relapsing NMO have very aggressive
disease with frequent and severe exacerbations and a poor prognosis.
Region-restricted episodes of CNS
inflammatory demyelination in persons without prior symptoms often represent
the initial manifestation of MS, although some may be a forme fruste of ADEM
(see later). The probability of recurrent demyelinating episodes has been the
subject of several important investigations, and several clinical features and
test results are of predictive value. Optic nerve, spinal cord, and brain stem
are the most common sites of these recurrent monosymptomatic events, and the
time profile follows that of MS relapses. The pathogenesis, pathophysiology,
epidemiology, clinical features, associated disorders, differential diagnosis,
evaluation, and management are the same as in MS and are discussed previously.
In these cases, the prognosis for
visual recovery after each episode of optic neuritis is good and most patients
regain normal visual acuity. Profound visual loss, recurrent optic neuritis,
and age older than 35 are associated with a higher risk for poor recovery. Investigators
have concluded that recurrent multifocal demyelinating episodes, fulfilling the
diagnostic requirements of CD MS, develop in 50 percent or more of patients
after isolated optic neuritis when follow-up is extended beyond 20 years.а аMost of this risk is incurred within the
first few years, although significant risk may continue into the fourth decade
after the event. Children much more often develop simultaneous bilateral optic
neuritis and have a lower risk for subsequent MS than adults. Factors that are
associated with an increased risk of developing MS as a disseminated
illness are the presence of venous sheathing, recurrent optic neuritis, family
history of MS, white race, previous vague or nonspecific neurological symptoms,
and the presence of OCBs, elevated IgG index, or IgG synthesis rate in CSF.
Head MRI gives the most strongly predictive information. The relative risk of
one or more cerebral white matter lesions, found in approximately 50 percent of
optic neuritis patients, is 3 to 14. Of the 44 patients with monosymptomatic
optic neuritis in one study, 82 percent of those with abnormal MRI fulfilled
the diagnosis of MS within 5 years whereas only 6 percent of those with normal
or nonspecific findings on MRI developed MS.а аThe Optic Neuritis Treatment Trial also found
an increased risk of MS in those with cerebral white matter lesions on MRI
(27.7 percent of those with an abnormal head MRI vs. 9.3 percent of those with
a normal head MRI after 3 years of follow-up).а аBoth of these studies found that a higher
number of lesions correlated with an even greater risk of MS.
The severity of acute transverse
myelitis is inversely related to the risk of acquiring further symptomatic
demyelinating lesions. Complete transverse myelitis with profound loss of
motor, sensory, and sphincter function imparts a relatively low risk of 3 to 14
for the later diagnosis of MS. Partial transverse myelitis with preservation of
significant motor function at peak is associated with a much higher incidence
of MS. Head MRI further delineates the risk. In a study by Ford and associates,
11 of 12 patients with partial transverse myelopathy and cerebral white matter
lesions on MRI developed MS within 3 years of follow-up whereas only 1 of the 3
patients with normal MRI progressed to MS.а аExcluding the 2 patients with complete
transverse myelopathy in Morrissey's study, 59 percent of the patients with an
isolated spinal cord syndrome and abnormal head MRI met the criteria for MS
during a 5-year follow-up and 11 percent of patients with normal MRI had
recurrences of multifocal demyelination.а а
Although monosymptomatic brain stem
demyelination is not as common as either optic neuritis or acute transverse
myelitis, similar conclusions have been reached. In the only study available,
two thirds of these patients with cerebral white matter lesions detected on MRI
developed MS within 5 years, compared with none of 5 patients with normal head
MRI.
As mentioned earlier, there is no
spontaneous animal model that closely resembles MS. EAE is the most widely
studied animal model of this disease. EAE is an antigen-specific,
T-cell-mediated autoimmune disease that can be induced in many species,
although rat and mice models predominate in the literature. Acute EAE is a
monophasic illness that more closely resembles ADEM. Chronic-relapsing EAE
closely mimics the clinical course of MS with repeated clinical relapses from
which the animal makes an incomplete recovery; some animals develop a slow
progressive course after several relapses. Although there is considerable
variability in the various EAE models, several closely parallel the
pathological picture of MS with perivascular inflammation and primary
demyelination initially and subsequent gliosis and axonal loss.
Studies in EAE have advanced our
understanding of the various stages of disease initiation that may underlie the
MS disease process, including the initial immune activation of T cells by
encephalitogenic antigens and factors that influence T cell recognition; TCR
restriction; the genetic influences on disease resistance, susceptibility, and
recovery; T cell/macrophage interactions; the various roles of soluble
mediators of inflammation (including TH1 and TH2 cytokines); factors regulating
blood-brain barrier permeability; T cell/adhesion molecule interactions;
factors influencing oligodendrocyte function and survival; and possible ways to
reduce astrocytic proliferation and induce remyelination.
For decades, investigators have used
EAE to screen for potentially effective therapies. Recent work has focused on
the chronic-relapsing EAE model, extending the multitude of previous studies of
immunosuppressive drug therapies. Current work includes strategies to enhance
TH2 cytokine production and block TH1 cytokine function; therapies that target
T-cell subsets, class II molecules of the major histocompatibility complex, and
TCRs used for the recognition of encephalitogenic antigens (using monoclonal
antibodies, altered peptide analogues, and T-cell vaccination studies that
target TCR variable regions). EAE has been used to enhance understanding of the
many possible mechanisms whereby interferons may influence immunemediated CNS
injury and to explore the possibility that antigen-specific immunotherapy may
ultimately be applicable to patients through either oral tolerance
("bystander suppression," anergy or clonal deletion) or with peptide
analogues to encephalitogenic antigens.
Another widely studied animal model
is Theiler's murine encephalomyelitis virus model. Intracranial inoculation
with Theiler's virus leads to chronic infection and chronic inflammatory
demyelination. Studies have shown that immune suppression ameliorates the
pathological damage in this model, verifying that it is the immune response and
not the viral infection that is responsible for the chronic demyelination. TMEV
has been particularly useful in exploring a number of possible mechanisms of
inducing remyelination in the setting of chronic demyelination. As outlined
earlier, both polyclonal antispinal cord immunoglobulins and monoclonal
antibodies directed against several protein antigens and chemical haptens have
been shown to promote extensive CNS remyelination in TMEV. This work has led to
two phase II clinical trials of human immunoglobulin in patients with optic
neuritis and multiple sclerosis.
Acute disseminated encephalomyelitis
is a monophasic inflammatory demyelinating disorder that characteristically
begins within 6 weeks of an antigenic challenge such as infection or
immunization. It occurs more often in the young and causes the rapid
development of multifocal or focal neurological deficits. Perivenous
inflammation, edema, and demyelination are the pathological hallmarks of ADEM,
although these lesions commonly enlarge and coalesce, forming lesions
pathologically indistinguishable from MS. Moreover, perivascular changes
typical of ADEM are common in patients with MS. There is considerable overlap
in the epidemiological, clinical, CSF, imaging, and pathological features
between ADEM and MS, often making it difficult to distinguish between the two
with reasonable confidence when encountering patients with a single
demyelinating event.
Pathogenesis and
Pathophysiology. ADEM closely resembles EAE both clinically and
pathologically and is most likely due to a transient autoimmune response toward
myelin. The occurrence of ADEM after vaccination with the rabbit spinal cord
preparation of rabies virus led to the discovery of EAE. Infections and
non-CNS-containing vaccinations may induce ADEM by molecular mimicry or by
activating autoreactive T-cell clones in a nonspecific manner. Lymphocyte
reactivity toward MBP has been identified in blood and CSF from patients with
ADEM, but its absence in others indicates a role for other antigens.
Epidemiology and
Risk Factors. ADEM can occur at any age but, perhaps because of the
higher frequency of immunization and exposure to new antigens, it is most
common during childhood. Unlike MS, both sexes are affected with equal
frequency. No association has been noted with pregnancy.
ADEM has been reported to follow a
number of different immunizations, usually within 6 weeks, including those for
pertussis, diphtheria, measles, mumps, rubella, and influenza (postvaccination
ADEM). However, the only epidemiologically and pathologically proven
association is with rabies vaccination, which also causes demyelinating
peripheral neuropathies. The original Pasteur rabies vaccine, prepared in
rabbit spinal cord, was associated with an incidence of ADEM of approximately 1
per 3,000 to 35,000 vaccinations and is no longer in use. A later vaccine, made
in duck embryo, which contains little neural tissue, carries a risk for ADEM of
1 per 25,000 vaccines. The use of human diploid cell lines, which contain no
nervous system tissue, for the production of rabies vaccine has virtually
eliminated the risk of ADEM. The association of bee stings with ADEM has also
been reported.
Parainfectious ADEM usually follows
onset of the infectious illness, often during the recovery phase, but because
of the latency between pathogen exposure and illness it may precede clinical
symptoms of infection or the two may occur simultaneously. The most commonly
reported associated illness is a nonspecific upper respiratory tract infection.
There have been a vast number of specific infections associated with ADEM, such
as virus infections (including rubella, mumps, herpes simplex,
varicella-zoster, Epstein-Barr, cytomegalovirus, influenza, and coxsackievirus)
and infection with Mycoplasma, Borrelia burgdorferi, and Leptospira.
Measles carries the highest risk for ADEM of any infection, occurring in 1 per
400 to 1,000 cases. Although ADEM has been reported in association with measles
immunization, the risk is far lower than the risk of acquiring measles and its
neurological complications.
Clinical Features
and Associated Disorders. A prodrome of headache, low-grade fever, myalgias,
and malaise often precedes the onset of ADEM by a few days. Neurological
symptoms develop rapidly and are commonly associated with encephalopathy,
stupor, coma, meningismus, and seizures. A variety of neurological
manifestations may occur, reflecting the focal or multifocal involvement of
brain, brain stem, cerebellum, optic nerves, and spinal cord. The mortality
rate is generally 10 to 25 percent. Peak severity occurs within several days,
and recovery may begin soon afterward. More than 50 percent of survivors have a
marked recovery with no or minimal functional impairment. Occasionally, ADEM
may evolve over a few months and there may be a second clinical deterioration
or subacute progression for a time. In these unusual cases, the distinction
from MS is difficult.
Differential
Diagnosis. One of the primary concerns after a single
demyelinating episode is whether other bouts can be expected (e.g., MS).
Several features may tip the balance toward one or the other, but the proper
diagnosis becomes apparent only with time. Classically, ADEM is characterized
by the multifocal involvement at onset whereas MS often presents with
monosymptomatic deficits such as optic neuritis. However, ADEM may cause
unifocal symptoms and MS may present with multifocal CNS involvement,
especially in children. The monosymptomatic deficits caused by ADEM are more
commonly severe, such as bilateral optic neuritis and complete transverse
myelitis. Although OCBs occur transiently in about one third of ADEM cases,
their persistence implies a diagnosis of MS. The subsequent disappearance of
OCBs, when performed by consistent techniques, is evidence against MS. The MRI
appearance of these two disorders is often identical, аbut the
presence of basal ganglia or cortical lesions, or large globular white matter
lesions, is more frequent in ADEM.
The fulminant development of ADEM is
distinctive but not pathognomonic, because a rare form of MS known as Marburg's
MS is also rapid in onset and often deadly. The appearance of brain stem,
periventricular, and multiple, large cerebral white matter lesions and the
presence of OCBs may distinguish Marburg's variant from ADEM.
On rare occasions, inflammatory
demyelinating lesions may reach a large size and resemble tumors (especially
lymphoma) on MRI, necessitating biopsy for clarification. There is usually one
dominant lesion, but smaller separate lesions may be identifiable. These have
been referred to as both ADEM and MS in the literature. The prognosis for
recovery is often quite good, although approximately one third suffer
subsequent attacks. Some develop typical MS, whereas others have recurring
tumor-like lesions. The term multiphasic ADEM has been used when
patients have large recurrences in the same location, and relapsing ADEM
refers to recurrences at different sites. The relationship of these entities
with MS is unclear.
Balo's concentric sclerosis refers
to the pathological finding of alternating bands of demyelination and
remyelination. These patients typically have large lesions and subacute
deficits similar to those described earlier. Typical demyelinating lesions
commonly coexist, and rarely CD MS patients are noted to have similar-appearing
lesions. The reason for this peculiar alternating pattern is unknown.
Schilder's myelinoclastic diffuse
sclerosis is another rare condition that may be confused with ADEM or other
demyelinating conditions. This is a progressive demyelinating disorder that
usually begins in childhood. The features are often atypical and include
dementia, aphasia, homonymous hemianopia, seizures, psychosis, elevated
intracranial pressure, and the absence of OCBs. The most characteristic finding
is the presence of two large, roughly symmetrical lesions on MRI, one in each
hemisphere. The diagnosis is made by excluding the known inherited
leukodystophies, especially adrenoleukodystrophy.
Management.
Treatment with intravenous methylprednisolone seems to halt progression and
allow recovery to begin sooner, just as with MS. Plasma exchange can be tried
in those with severe deficits and little response to corticosteroids.